Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Oasis Medical, Inc.
483
•Oasis Medical, Inc.•January 27, 2025

Oasis Medical, Inc. – FDA 483, Jan 27, 2025

Record Details

An FDA inspection of Oasis Medical, Inc., a sterile drug manufacturer and distributor in Glendora, CA, was conducted from January 15-27, 2025. The inspection revealed significant deficiencies across the company’s quality, laboratory, production, and facilities/equipment systems, indicating a failure to comply with Current Good Manufacturing Practices (CGMP).

Key violations included a systemic failure to thoroughly investigate unexplained discrepancies and out-of-specification results, such as sterility failures and bioburden exceedances, for OTC Ophthalmic Lubricant drug products, with affected batches being released without adequate scientific justification. The firm’s quality unit lacked appropriately trained and educated personnel, failed to implement essential GMP training, and neglected to conduct annual product reviews or visual examinations of reserve samples, some of these being repeat observations from prior inspections.

Further issues encompassed an inadequate stability program, which lacked sufficient data to support product shelf life and omitted critical active ingredient identity and strength testing. Laboratory controls were compromised by unqualified equipment, poor maintenance, and unvalidated computer systems with shared access credentials. Production controls were found deficient, particularly in the visual inspection program (lacking defect criteria, acceptance limits, and personnel requalification) and process revalidations, including sterilization and hold time studies. Additionally, equipment qualification and cleaning validation were absent, and the cleanroom environmental monitoring program, along with material introduction methods, was inadequate, posing contamination risks.

Oasis Medical, Inc. is required to promptly address these serious observations by implementing robust corrective and preventive actions to ensure the quality, safety, and purity of its sterile drug products.

Company
Oasis Medical, Inc.
Inspection date
January 27, 2025
Product type
drugs
Office
Los Angeles District Office
People
  • Youkeun Kim
  • Crystal Monroy
  • Ngozi G. Offor (issuing_officer)
  • Claudia G Perez-Kozlowski
  • Claudia M. Perez-Kasmarski
View Company Profile

ID · bd25208f-6371-4abc-80c8-f78c4380ee21

Other documents for Oasis Medical, Inc.
  • WARNING_LETTER - 2025-01-27January 27, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Oasis Medical, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.